Ocular neuropathic pain

OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

Retrieved on: 
Thursday, May 19, 2022
Uveitis, American depositary receipt, Telephone, Form, G protein-coupled receptor, Company, U.S. Securities and Exchange Commission, GPCR, Patient, LSE, Allergic conjunctivitis, SEC filing, DED, ADSS, IND, Industry, Pathology, Sale, Therapy, Regulation, ThinkEquity, Ocular neuropathic pain, State Street, Prospectus, Security (finance), GLOBE, Pharmaceutical industry

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the closing of its underwritten public offering of 625,000 American Depository Shares (the ADSs) at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.

Key Points: 
  • LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced the closing of its underwritten public offering of 625,000 American Depository Shares (the ADSs) at a public offering price of $4.00 per share, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering expenses.
  • 333-263326) relating to the shares was filed with the Securities and Exchange Commission (SEC) and became effective on May 16, 2022.This offering is being made only by means of a prospectus.
  • OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a life sciences company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing

Retrieved on: 
Monday, May 16, 2022
Uveitis, Telephone, Form, Company, G protein-coupled receptor, U.S. Securities and Exchange Commission, Exercise, GPCR, Patient, LSE, Allergic conjunctivitis, DED, ADSS, ADS, IND, Industry, Nasdaq, Biotechnology, Pathology, Sale, Therapy, ThinkEquity, Ocular neuropathic pain, State Street, American depositary receipt, Prospectus, GLOBE, Pharmaceutical industry

LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of an underwritten public offering of 625,000 American Depositary Shares (the ADSs) at a public offering price of $4.00 per ADS.

Key Points: 
  • LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (OKYO Pharma or the Company), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of an underwritten public offering of 625,000 American Depositary Shares (the ADSs) at a public offering price of $4.00 per ADS.
  • In addition, OKYO Pharma has granted the underwriters a 45-day option to purchase up to an additional 93,750 ADSs to cover over-allotments, if any.
  • The Company has received approval to list its ADSs on the Nasdaq Capital Market under the symbol OKYO, and the ADSs are expected to begin trading on May 17, 2022.
  • OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.

OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
BAM, Official List, UK, Financial Conduct Authority, Poster, Cornea, Biotechnology, Pain, Perception, LSE, NCP, ARVO, MAP, Annual general meeting, Association, Tufts Medical Center, Eye, Regulation of tobacco by the U.S. Food and Drug Administration, Duane syndrome, Association for Research in Vision and Ophthalmology, Nociception, MD, Food, Model, Molecule, GLOBE, Ocular neuropathic pain, Steroid, Infection, London Stock Exchange Group, Technology, CO, Company, MA, Industry, Quality of life, Risk, Peripheral neuropathy, Interim, London Stock Exchange, Research, Pharmaceutical industry, Vaccine, Ophthalmology

LONDON, April 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that two presentations will be given on OKYO drug candidates OK-101 and OK-201 at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.

Key Points: 
  • OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.
  • Millions of people suffer from ocular pain every year with no treatment approved by the U.S. Food and Drug Administration for this condition.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Nervous system, Pain, Organ systems, Neuropathic pain, Analgesic, Peripheral neuropathy, Gabapentin, Hyperalgesia, Ocular neuropathic pain, Opioid, Ketamine

Importantly, OK-201 demonstrated a reduced corneal pain response similar to that of gabapentin, a commonly used oral drug for neuropathic pain.

Key Points: 
  • Importantly, OK-201 demonstrated a reduced corneal pain response similar to that of gabapentin, a commonly used oral drug for neuropathic pain.
  • These observations demonstrated preclinical \xe2\x80\x98proof-of-concept\xe2\x80\x99 for the topical administration of OK-201 as a potential non-opioid analgesic for ocular pain.
  • Current treatments for corneal pain are limited to short term NSAIDs, steroids, and oral gabapentin and opioids in severe cases.
  • Ocular neuropathic pain refers to the increased perception of pain in response to ordinarily non-painful stimuli and is often misdiagnosed as dry eye disease.

Medtronic Launches Efficio™ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMed™ II

Retrieved on: 
Thursday, January 23, 2020
Medicine, Health, Clinical medicine, Pain, Oncology, Intrathecal administration, Medtronic, Cancer pain, Spasticity, Neurological disorders, Intrathecal pump, Ocular neuropathic pain

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.

Key Points: 
  • DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.
  • Efficio also helps me manage pump refill dates, pump replacements, and monitor trends in dosing and patient function.
  • Efficio marks another step in our journey to simplify targeted drug delivery therapy, said Charlie Covert, vice president and general manager of the Targeted Drug Delivery business, which is part of the Restorative Therapies Group at Medtronic.
  • The SynchroMed II intrathecal drug delivery system offers a safe, proven, and effective way to manage chronic pain, cancer pain and severe spasticity for appropriate patients.

Neuropathic Pain Market and Forecast Analysis to 2026

Retrieved on: 
Tuesday, June 4, 2019
Pain, Organ systems, Perception, Nervous system, Neuropathic pain, Peripheral neuropathy, Neuralgia, Postherpetic neuralgia, Ocular neuropathic pain, EMA401

Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain.

Key Points: 
  • Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain.
  • Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.
  • Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
  • The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.

Global Pain Management and Surgical Devices Market 2018-2025 Featuring Abbott Labs, Avanos Medical, Boston Scientific, Djo Global, J&J, Medtronic, Merit Medicals System, Nevrocorp, Nuvectra & Stryker

Retrieved on: 
Monday, December 17, 2018
Pain, Perception, Medicine, Acute pain, RTT, Rheumatology, Neuropathic pain, Fibromyalgia, Arthritis, Surgery, Chronic pain, Ocular neuropathic pain

The "Pain Management and Surgical Devices Global Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pain Management and Surgical Devices Global Market" report has been added to ResearchAndMarkets.com's offering.
  • The pain management and surgical devices global market is expected to grow at a high single digit CAGR to reach $8,824.7 million by 2025.
  • The pain management and surgical devices market is mainly segmented by products, treatment type, application, end-users and by geography.
  • Pain is a debilitating condition, which can arise from arthritis, cancer, fibromyalgia and trauma, which includes neuropathic pain and nociceptive pain.

HealthStartNJ LLC invests in study to advance the treatment of neuropathic pain

Retrieved on: 
Thursday, October 4, 2018
Perception, Pain, Nervous system, Nociception, Neuropathic pain, Peripheral neuropathy, Chronic pain, Ocular neuropathic pain

Staal, PhD that focuses on the study and therapeutics of neuropathic pain, announced James M. Golubieski, president of NJHF.

Key Points: 
  • Staal, PhD that focuses on the study and therapeutics of neuropathic pain, announced James M. Golubieski, president of NJHF.
  • "Neuropathic pain is chronic, pathological pain caused by a lesion of the nervous system resulting in a significant decrease in the quality of life of an affected individual.
  • "Chronic neuropathic pain is very common, however existing treatments offer only limited relief to a minority of patients," explained George F. Heinrich, M.D., vice chair and CEO of HealthStartNJ.
  • "This study by Paracelsus will hopefully one day lead to an effective treatment for the debilitating effects of neuropathic pain."